A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C
Study Details
Study Description
Brief Summary
This is a prospective non-therapeutic observational study in NP-C patients. The aim is to characterize the individual patient disease progression profile through the historical and 6 months prospective evaluation of clinical, imaging, biological(biomarkers) and quality of life data.
Patients will be offered enrollment into a Phase II/III study on arimoclomol at the end of the study.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
NP-C Patients NPC type 1 or 2 patients aged 2-18 years |
Outcome Measures
Primary Outcome Measures
- NP-C clinical disease severity [at week 0 and week 24-28]
Change in NP-C Clinical Severity scale
- Quality of life questionnaire (EQ-5D-Y) [at week 0 and week 24-28]
Change in the Quality of life
- Ultrasonographic evaluation of liver and spleen [at week 0 and week 24-28]
Changes in the size and/or characteristics of the liver and spleen (assessed by ultrasound).
- Oxysterol [at week 0 and week 24-28]
Change in Oxysterol concentrations
- NPC clinical symptoms [at week 0 and week 24-28]
Change in NPC clinical symptoms
- NPC protein [at week 0 and week 24-28]
Change in NPC protein concentrations
Secondary Outcome Measures
- Safety Parameters [at week 0 and week 24-28]
Adverse events (AEs) (disease related and treatment related), haematology, clinical chemistry, physical examination, vital signs and electrocardiogram (ECG).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written informed consent (and assent if appropriate to local laws and regulations) prior to any study-related procedures;
-
Males and females aged from 2 years to 18 years and 11 months;
-
Patients of any ethnic background will be eligible for this study;
-
Patient weight ≥15th percentile of body mass index (BMI) for age according to the World Health Organisation (WHO) standards;
-
Diagnosis of Niemann Pick disease Type C (NP-C), either NPC1 or NPC2;
-
NP-C diagnosis genetically confirmed (deoxyribonucleic acid [DNA] sequence analysis);
-
Both NPC1 and NPC2 patients are eligible;
-
Presenting at least one neurological symptom of the disease (for example, but not limited to, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, or dysphagia);
-
Ability to walk either independently or with assistance;
-
Ability to travel to the corresponding clinical trial site repeatedly (every 6 months) for evaluation and follow-up;
-
Treated or non-treated with miglustat;
-
If a patient is under prescribed treatment with miglustat, it has to be under stable dose of the medication for ≥ 3 continuous months prior to inclusion in the study;
-
Sexually active patients must be willing and able to use an adequate method of contraception throughout the study, for example: diaphragm + spermicide; intrauterine contraceptive device; oral contraceptives; implant; injection of a progestogen medication;
-
Ability to comply with the protocol-specified procedures/evaluations and scheduled visits;
-
Willing to participate in all aspects of trial design including serial blood sampling, skin biopsies and imaging (ultrasonography) collections.
Exclusion Criteria:
-
No written informed consent obtained from the patient or their parent(s)/legal guardian(s) (and assent if appropriate to local laws and regulation) before any study related procedures;
-
Recipient of a liver transplant or planned liver transplantation;
-
Patients with uncontrolled severe epileptic seizures period (at least 3 consecutive severe epileptic seizures that required medication) within 2 months prior to the written consent. This includes patients with ongoing seizures that are not stable in frequency or type or duration over a 2 month period prior to enrollment, requiring change in dose of antiepileptic medication (other than adjustment for weight) over a 2 month period prior to enrollment, or requiring 3 or more antiepileptic medications to control seizures;
-
Neurologically asymptomatic patients;
-
Severe liver insufficiency (defined as hepatic laboratory parameters, aspartate transaminase [AST] and alanine transaminase [ALT] greater than three-times the upper limit of normal for age and gender;
-
Severe renal insufficiency, with serum creatinine level greater than 1.5 times the upper limit of normal ;
-
Severe manifestations of NP-C disease that would interfere with the patient's ability to comply with the requirements of this protocol;
-
In the opinion of the Investigator, the patient's clinical condition does not allow for the required blood collection and/or skin biopsies as per the protocol-specified procedures;
-
Treatment with any IMP within 4 weeks prior to the study enrollment;
-
Treatment with any IMP during the study in an attempt to treat NP-C;
-
Current participation in another trial is not permitted unless it is a non-interventional study and the sole purpose of the trial is for long-term follow up/survival data (registry);
-
Patients will be excluded if there is a confirmed risk linked to the MRI procedure to be performed in the subsequent therapeutic interventional study [i.e.: implanted cardiac pacemaker or implantable cardioverter defibrillator, implanted neural pacemakers, cochlear implants, implanted metallic foreign bodies in the eye or CNS (such as a CNS aneurysmal clip), any form of implanted wire or metal device that may concentrate radio frequency fields and/or confirmed history of unexpected serious adverse reaction to sedation or anesthesia (if sedation is necessary)];
-
Patients will be excluded if there is a confirmed risk linked to the skin punch biopsy procedure like severe thrombocytopaenia, at investigator's discretion.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University Hospital Copenhagen (Rigshospitalet) | Copenhagen | Denmark | 2100 | |
2 | CHU de Montpellier | Montpellier | France | ||
3 | Hôpital Trousseau | Paris | France | ||
4 | Villa Metabolica Mainz | Mainz | Germany | 55131 | |
5 | Klinikum der Universistat, Munchen | Munich | Germany | ||
6 | Istituto Carlo Besta (Milano) | Milan | Italy | 20133 | |
7 | Azienda Ospedaliera San Gerardo | Monza | Italy | 20900 | |
8 | Università Federico II | Napoli | Italy | 80138 | |
9 | Ospedale Pediatrico Bambino Gesù | Rome | Italy | 00146 | |
10 | Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" | Udine | Italy | ||
11 | The Children´s Memorial Istitute Warsaw | Warsaw | Poland | 04-730 | |
12 | Hospital Vall D'Hebron | Barcelona | Spain | 08035 | |
13 | Hospital Quirón | Zaragoza | Spain | 50006 | |
14 | Inselspital, University Hospital Bern | Bern | Switzerland | 3010 | |
15 | Birmingham Children's Hospital | Birmingham | United Kingdom | B4 6NH | |
16 | Great Ormond Street Hospital | London | United Kingdom | WC1N 3JH |
Sponsors and Collaborators
- KemPharm Denmark A/S
Investigators
- Principal Investigator: Karl-Eugen Mengel, Villa Metabolica, Mainz, Germany
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CT-ORZY-NPC-001
- 2014-005194-37